
Long-Term Extension Data Demonstrates Sustained Effect of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Newly announced data from the open-label extension (OLE) period of the phase 2 EMPhASIS trial (NCT03846219) showed that patients with relapsing-remitting multiple sclerosis (RRMS) treated with vidofludimus calcium (Immunic) maintained low rates of …